Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Breast cancer
Phase 2 STEMVAC DNA vaccine targets CDH3/CD105/YB-1/MDM2/SOX2 in residual TNBC.
University of Washington is running a randomized Phase 2 adjuvant study testing STEMVAC, a multiantigen plasmid DNA cancer vaccine designed to induce T-cell responses against five “aggressiveness/stemness”-associated…
NCT07721259 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 2 ASP-1929 EGFR-targeted photoimmunotherapy (cetuximab–IR700 conjugate) in pancreatic cancer.
This open-label Phase 2 BrUOG 438 study tests ASP-1929 photoimmunotherapy (PIT) as a peri-operative, EGFR-targeted cytotoxic immune-activating approach for locally advanced or borderline resectable pancreatic…
NCT07698613 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 177Lu-DTPA-omburtamab compartmental radioimmunotherapy targets B7-H3 (CD276)
This Phase 1, dose-escalation compartmental radioimmunotherapy (cRIT) study tests intrathecal/intraventricular delivery of 177Lu-DTPA-omburtamab, a B7-H3 (CD276)-targeting murine monoclonal antibody chelated with…
NCT07698899 First-in-human - New trial
Multiple solid tumors
Phase 1 carfilzomib selective proteasome inhibitor via hepatic artery infusion pump for liver metastases
This National Cancer Institute (NCI) Phase 1, open-label, single-arm study tests whether carfilzomib—a selective proteasome inhibitor (approved as Kyprolis by Amgen)—can be safely delivered continuously through an…
NCT07715903 Exploratory - New trial
Multiple solid tumors
Phase 1/2a VBC108 CLDN18.2×CDH17 bispecific topo1 inhibitor ADC in advanced solid tumors.
This first-in-human, multicenter, open-label Phase 1/2a study tests VBC108, a CLDN18.2- and CDH17-directed bispecific antibody-drug conjugate from VelaVigo Bio that delivers a topoisomerase I inhibitor payload to…
NCT07700160 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b DBC-664 — Undisclosed MOA/target (first-in-human agent)
No disclosed MOA. We do not include details of trials without this basic information.
NCT07705035 First-in-human - Trial result Spotlight
Non-small cell lung cancer
Selpercatinib (RET inhibitor) slashes recurrence risk in resected RET fusion+ NSCLC (2-year EFS 92% vs 61%)
Selpercatinib is an oral, highly selective RET tyrosine kinase inhibitor (CNS-penetrant) tested as adjuvant targeted therapy in the Phase 3, double-blind LIBRETTO-432 trial (NCT04819100) in RET fusion–positive stage…
NCT04819100 - Trial result Spotlight
Non-small cell lung cancer
Sunvozertinib (EGFR exon20ins TKI) extends PFS vs carbo/pem chemo in 1L EGFR exon20ins NSCLC (WU-KONG28)
Sunvozertinib is an oral EGFR tyrosine kinase inhibitor designed to inhibit EGFR exon 20 insertion mutations, tested head-to-head vs platinum doublet in the confirmatory multinational Phase 3 WU-KONG28 trial…
NCT05668988 - Trial result
Non-small cell lung cancer
Nivolumab (PD-1 inhibitor) Fails to Improve DFS vs Observation After NSCLC Resection
Nivolumab is an anti–PD-1 checkpoint inhibitor tested as *adjuvant* therapy after upfront surgery (and after completion of planned adjuvant chemotherapy and/or radiotherapy) in the ECOG-ACRIN EA5142 Phase 3 trial…
NCT02595944 - Trial result
Non-small cell lung cancer
Silevertinib (BDTX-1535), a covalent 4th-gen EGFR TKI, drives 60% ORR and 86% CNS responses in 1L non-classical EGFR NSCLC
Silevertinib (BDTX-1535) is a fourth-generation, covalent EGFR tyrosine kinase inhibitor designed to cover non-classical EGFR mutations (including P-loop/αC-helix–compressing [PACC] variants) with high CNS…
NCT05256290 - Trial result
Liver and bile duct cancer
Pemigatinib (FGFR1–3 inhibitor) improves PFS and ORR vs Gem/Cis in 1L FGFR2-rearranged mCCA (FIGHT-302)
Pemigatinib is an oral selective FGFR1–3 tyrosine kinase inhibitor evaluated as first-line therapy in the randomized global Phase 3 FIGHT-302 trial (NCT03656536) in previously untreated unresectable/metastatic…
NCT03656536 - Trial result
Liver and bile duct cancer
GemCis + Lenvatinib + Adebrelimab (VEGFR/FGFR/PD-L1) Hits 46% ORR in iCCA
Adebrelimab is a PD-L1 antibody and lenvatinib is an oral VEGFR/FGFR/RET/KIT multi-kinase inhibitor added to gemcitabine/cisplatin in a prospective, multicenter, single-arm Phase 2 first-line trial for…
NCT06298968 - Trial result
Kidney cancer
Cabozantinib (VEGFR/MET/AXL TKI) + nivolumab (PD-1) sustains PFS/OS gains vs sunitinib in aRCC with liver metastases
Cabozantinib is a multikinase VEGFR/MET/AXL inhibitor paired here with nivolumab, a PD-1 checkpoint inhibitor; this exploratory CheckMate-9ER (Phase 3; NCT03141177) subgroup analysis evaluated first-line clear-cell…
NCT03141177 - Trial result
Kidney cancer
HC-7366 (GCN2 activator; ISR/metabolic-stress agonism) + belzutifan (HIF-2α inhibitor) posts 37% BORR in post–PD-(L)1/VEGF-TKI ccRCC
HC-7366 is an oral, selective activator of GCN2 kinase designed to drive the integrated stress response and suppress HIF/cell-cycle programs; belzutifan is an oral HIF-2α inhibitor. In this Phase 1b open-label…
- Trial result
Sarcoma and GIST
PRAME-directed TCR-T (anzu-cel/IMA203CD8) hits 50% cORR with 12.7-mo DoR in R/R synovial sarcoma
Anzutresgene autoleucel (anzu-cel, IMA203) is an autologous PRAME-directed TCR T-cell therapy (HLA-A*02:01–restricted), while IMA203CD8 adds an engineered CD8 co-receptor to broaden tumor-cell recognition by both…
NCT03686124 - Trial result
Multiple myeloma
D-VRd doubles sustained MRD negativity vs VRd in transplant-ineligible/deferred NDMM
Daratumumab is an anti-CD38 monoclonal antibody added to bortezomib/lenalidomide/dexamethasone to create a quadruplet regimen for newly diagnosed multiple myeloma patients who are transplant-ineligible or…
NCT03652064 - Trial result
Myeloproliferative neoplasms
Imetelstat (telomerase inhibitor) doubles mOS vs real‑world BAT after ruxolitinib in R/R myelofibrosis
Imetelstat (IME) is a first-in-class telomerase inhibitor evaluated in IMbark (Phase 2; NCT02426086) in intermediate‑2/high‑risk myelofibrosis after Janus kinase inhibitor (JAKi) relapse/refractoriness. In this…
NCT02426086 - Trial result
Cervical and other gynecologic cancers
Hypofractionated pelvic RT (37.5Gy/15fx) + weekly cisplatin shows similar pCR vs standard 50Gy/25fx in LACC surgery cohort
Phase II randomized trial (NCT03750539) in FIGO IB3–IIIC1 locally advanced cervical cancer tested concurrent weekly cisplatin with either standard-fractionation EBRT (50Gy/25fx) or hypofractionated EBRT…
NCT03750539 - Trial result
Cervical and other gynecologic cancers
CRB-701 (SYS6002) Nectin-4–targeted MMAE ADC shows early ~38% unconfirmed ORR in R/M cervical cancer
CRB-701 is a next-generation Nectin-4–targeting antibody–drug conjugate (ADC) delivering MMAE, evaluated in a Phase 1/2 dose-escalation/optimization study (NCT06265727) in recurrent/metastatic cervical cancer after…
NCT06265727 - Trial result
Chronic lymphocytic leukemia
BR induction + BCL2 inhibitor venetoclax/CD20 rituximab consolidation delivers 83% BM uMRD and 87.5% 3-year PFS in frontline CLL
Short-course bendamustine/rituximab (alkylator + anti-CD20) followed by venetoclax/rituximab (BCL2 inhibitor + anti-CD20) was tested as a time-limited, single-arm Phase 2 regimen in previously untreated CLL/SLL…
NCT03609593 - Trial result
Lymphoma
Liso-cel (CD19 CAR-T) Delivers 38% 5-Year OS in R/R LBCL, Supporting a “Plateau”
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T cell therapy evaluated in the Phase 1 TRANSCEND NHL 001 program in relapsed/refractory large B-cell lymphoma (R/R LBCL) after ≥2 prior lines.…
NCT02631044 - Trial result Spotlight
Skin cancer (non-melanoma)
Pembrolizumab (PD-1) cuts MCC-specific relapse events in resected Merkel cell carcinoma, with signal for better distant control
Pembrolizumab is an anti–PD-1 checkpoint inhibitor tested as adjuvant therapy in the randomized Phase III STAMP trial (EA6174; NCT03712605) after complete resection of stage I (no SLNB) to IIIB Merkel cell carcinoma:…
NCT03712605 - Trial result
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) cuts seizure rates ~80% and delays QoL decline in INDIGO grade 2 glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2 evaluated vs placebo in the Phase 3 INDIGO trial (NCT04164901) in treatment-naïve (post-surgery only) grade 2 mIDH1/2 diffuse glioma…
NCT04164901 - Trial result Spotlight
Melanoma
Intismeran autogene + pembrolizumab sustains 5-year RFS/DMFS benefit in resected melanoma
Intismeran autogene, also known as V940 or mRNA-4157, is Moderna/Merck’s individualized neoantigen mRNA therapy encoding up to 34 patient-specific tumor neoantigens, designed to broaden tumor-specific T-cell…
NCT03897881 - Trial result
Small cell lung cancer
Lurbinectedin (DNA-binding transcription inhibitor) + atezolizumab extends Q‑TWiST vs atezolizumab in ES‑SCLC maintenance
Lurbinectedin (a selective inhibitor of oncogenic transcription via DNA binding) plus the PD‑L1 inhibitor atezolizumab was evaluated as first-line maintenance in the Phase 3 IMforte trial (NCT05091567) in ES‑SCLC…
NCT05091567 - Trial result
Small cell lung cancer
ABBV-706 (SEZ6-targeted Top1i ADC) posts 52% ORR in relapsed/refractory SCLC, RP2D set at 1.8mg/kg Q3W
ABBV-706 is a SEZ6-directed antibody–drug conjugate delivering a topoisomerase-1 inhibitor (Top1i) payload, evaluated in an open-label Phase 1 dose-escalation/optimization/expansion trial across advanced solid tumors…
NCT05599984 - Trial result
Liver and bile duct cancer
Tremelimumab (CTLA-4) + durvalumab (PD-L1) ± lenvatinib (VEGFR TKI) with TACE improves PFS in embolization-eligible unresectable HCC (EMERALD-3)
Tremelimumab + durvalumab (STRIDE: single priming dose tremelimumab plus Q4W durvalumab) was combined with transarterial chemoembolization (TACE) with or without lenvatinib (VEGFR/FGFR-targeting multikinase…
NCT05301842 - Trial result
Sarcoma and GIST
Velzatinib (IDRX-42) selective KIT inhibitor drives 61% ORR in 1L GIST; 13.7-mo mPFS in 2L
Velzatinib (IDRX-42; subject to USAN approval) is a next-gen, selective KIT inhibitor designed for broad coverage across primary KIT exons 9/11 and common secondary resistance mutations (exons 13/14 ATP-binding…
NCT05489237 - Trial result
Sarcoma and GIST
Pimicotinib (CSF1R inhibitor) sustains ~76% ORR and improves knee ROM/PF across TGCT sites
Pimicotinib is an oral, highly selective CSF-1 receptor (CSF1R) inhibitor evaluated in the global Phase 3 MANEUVER trial (NCT05804045) in symptomatic, unresectable TGCT; this analysis reports longer-term outcomes by…
NCT05804045 - Trial result Spotlight
Acute myeloid leukemia and MDS
Ziftomenib (menin inhibitor) + venetoclax/azacitidine drives 46% CRc and frequent MRD negativity in R/R NPM1-mut AML
Ziftomenib is a potent, selective, oral menin inhibitor evaluated with venetoclax (BCL-2 inhibitor) plus azacitidine (hypomethylating agent) in KOMET-007, a Phase 1a/1b dose-escalation/expansion study in adults with…
NCT05735184
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.